BitNile.com to Launch March 1, 2023

BitNile Holdings, Inc.(NYSE American: NILE), a diversified holding company ("BitNile" or the "Company"), announced today that it plans to launch a next-generation marketplace, BitNile.com and "go live" March 1, 2023.

BitNile Holdings, Inc.(NYSE:NILE), a diversified holding company (“BitNile” or the “Company”), announced today that it plans to launch a next-generation marketplace, BitNile.com and “go live” March 1, 2023. BitNile.com is being developed as the premiere destination for exclusive goods and VIP experiences that readily can accept Bitcoin. BitNile.com’s development is led by Douglas Gintz, the President and Chief Product Officer of BitNile, Inc. The Company invites shareholders and the public to register for the initial launch using this link, https://BitNile.com/. Those signing up prior to the launch will be granted a future reward with details to follow.

Milton “Todd” Ault, III, the Company’s Executive Chairman, stated, “This has been many years in the making and are proud of the progress that Douglas Gintz and his team have made and look forward to becoming the premiere destination for exclusive goods and VIP experiences. We look forward to our launch on March 1, 2023.”

Total
0
Shares
Related Posts
Read More

$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO’s Q2 2023

Societal CDMO Inc. (NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics, reported financial results for the three and six months ended June 30, 2023.

SCTL

Read More

JNJ Rybrevant Receives Canadian Agency For Drugs and Technologies In Health Reimbursement Recommendation For The Treatment Of Adult Patients With Non-Small Cell Lung Cancer With Activating EGFR Exon 20 Insertion Mutations

Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Canadian Agency for Medicines and Health Technologies ( ACMTS ) recommended that RYBREVANT® ( amivantamab ) be reimbursed by public schemes for the treatment of adult patients with non-small cell lung cancer ( CPNPC ) locally advanced or metastatic, carriers of activating mutations for the insertion of exon 20 of the e

JNJ